A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Block, Geoffrey A; Fishbane, Steven; Rodriguez, Mariano; Smits, Gerard; Shemesh, Shay; Pergola, Pablo E; Wolf, Myles; Chertow, Glenn M

Block, Geoffrey A; Fishbane, Steven; Rodriguez, Mariano; Smits, Gerard; Shemesh, Shay; Pergola, Pablo E; Wolf, Myles; Chertow, Glenn M.

Affiliation

Block GA; Denver Nephrologists PC, Denver, CO. Electronic address: gablock@dnresearch.org.
Fishbane S; Hofstra-North Shore LIJ School of Medicine, Great Neck, NY.
Rodriguez M; Nephrology Service, IMIBIC, Hospital Universitario, Cordoba, Spain.
Smits G; Denver Nephrologists PC, Denver, CO.
Shemesh S; Keryx Biopharmaceuticals Inc, New York, NY.
Pergola PE; Renal Associates PA, San Antonio, TX.
Wolf M; Department of Medicine, Institute for Public Health and Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL.
Chertow GM; Stanford University School of Medicine, Palo Alto, CA.

Am J Kidney Dis ; 65(5): 728-36, 2015 May.

Article in En | MEDLINE | ID: mdl-25468387

Subject(s)
Key words

Chronic kidney disease (CKD); ferric citrate coordination complex (ferric citrate); fibroblast growth factor 23 (FGF-23); hemoglobin; iron repletion; iron-deficiency anemia; oral iron therapy; phosphate binder; randomized controlled trial; serum phosphate; transferrin saturation (TSAT); urinary phosphate excretion

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phosphates / Ferric Compounds / Anemia, Iron-Deficiency / Renal Insufficiency, Chronic / Hematinics Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Kidney Dis Year: 2015 Document type: Article Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google